Obesity and related metabolic diseases have become global public health problems, which are closely related to the occurrence of cardiovascular diseases, diabetes and certain cancers. Although traditional treatment methods such as diet control, exercise intervention and drug therapy have certain effects, they have problems such as poor compliance, limited therapeutic effect and significant side effects. AOD 9604 capsule is a synthetic 30-amino acid polypeptide. By mimicking the growth hormone-releasing peptide fragment, it can promote fat breakdown and inhibit fat accumulation, and has potential anti-tumor effects at the same time. However, the large molecular weight, strong hydrophilicity and easy enzymatic hydrolysis of AOD 9604 result in its low bioavailability and limit its clinical application.The rise of nanotechnology has brought revolutionary changes to drug delivery systems. Nanocarriers can achieve targeted delivery, sustained release and improved stability of drugs by regulating the particle size, surface charge and modification strategy of drugs. Chitosan, as a natural cationic polysaccharide, has excellent biocompatibility, biodegradability and low immunogenicity. The amino groups on its molecular chain can tightly bind to negatively charged cell membranes or mucous membranes, enhancing the mucosal permeability of drugs. In addition, chitosan nanocarriers can directly deliver drugs to the lymphatic system through lymphatic targeting technology, increase local drug concentration and reduce systemic toxicity.
|
|
|
Characteristics and Preparation of Chitosan Nanocarriers
The chemical structure and biological characteristics of chitosan
Chitosan is a natural polysaccharide produced by deacetylation of chitin (mainly existing in the shells of shrimps and crabs), and its chemical structure is composed of β-(1,4) -linked D-glucosamine and N-acetyl-D-glucosamine units. The biological characteristics of chitosan are mainly reflected in the following aspects:
Biocompatibility
Chitosan can be degraded in vivo by enzymes such as lysozyme into non-toxic glucosamine monomers, demonstrating excellent biocompatibility.
Biodegradability
The degradation rate of chitosan can be regulated by regulating its molecular weight, degree of deacetylation and environmental conditions.
Mucosal adhesion
Under acidic conditions, the amino groups on the chitosan molecular chain are protonated, endowing it with positive charge characteristics, enabling it to tightly bind to the negatively charged mucosa and prolonging the retention time of the drug on the mucosal surface.
Antibacterial property
The positive charge of chitosan can interact with the negative charge on the bacterial cell membrane, destroying the integrity of the cell membrane and thereby exerting an antibacterial effect.
The preparation method of chitosan nanocarriers
The preparation methods of chitosan nanocarriers mainly include ionic crosslinking method, covalent crosslinking method, self-assembly method and composite coagulation method.
Ion cross-linking method: By using multivalent anions such as sodium tripolyphosphate (TPP) to electrostatically interact with the amino groups of chitosan, a three-dimensional network nano-gel structure is formed. This method is simple to operate, has mild conditions and does not require organic solvents. It is the most commonly used method for preparing chitosan nanoparticles.
Covalent cross-linking method: Chitosan molecular chains are linked together through chemical cross-linking agents such as glutaraldehyde and kinesine to form stable nanoparticles. This method can improve the stability of nanoparticles, but it may introduce toxic crosslinking agents.
Self-assembly method: By taking advantage of the hydrophobic interactions or hydrogen bonds between chitosan molecules, nanoparticles are spontaneously formed. This method does not require a crosslinking agent, but the stability of nanoparticles is relatively poor.
Composite coagulation method: Chitosan is mixed with polymers of opposite charge (such as sodium alginate), and nanoparticles are formed through electrostatic interaction. This method can regulate the surface charge and particle size of nanoparticles.
Modification strategies of chitosan nanocarriers
To further enhance the targeting, stability and bioavailability of chitosan nanocarriers, researchers often adopt surface modification strategies.
Polyethylene glycol (PEG) modification
Introducing PEG chains on the surface of chitosan nanoparticles to form invisible nanoparticles reduces the adsorption of plasma proteins and prolongs the circulation time in the body.
01
Targeted ligand modification
By means of covalent binding or physical adsorption, targeted ligands such as folic acid, transferrin, and antibodies are modified on the surface of nanoparticles to achieve active targeting of specific cells or tissues.
02
Quaternary ammonium modification
By introducing quaternary ammonium groups, the positive charge density of chitosan is enhanced, and its solubility and mucosal adhesion under neutral conditions are improved.
03
Liposome combination
Chitosan nanoparticles are combined with liposomes to form hybrid nanoparticles, which combine the advantages of both and improve the encapsulation rate and stability of drugs.
04
Lymphatic targeting technology and its application in the delivery of AOD 9604
The anatomy and physiological functions of the lymphatic system
The lymphatic system is composed of lymphatic vessels, lymph nodes and lymphoid tissues, and it is an important channel for the transport of immune cells and the presentation of antigens. The connections between the endothelial cells of lymphatic vessels are looser than those in capillaries, allowing large molecules and nanoparticles to pass through. Lymph nodes are important nodes of the lymphatic system, rich in immune cells and capable of filtering pathogens and tumor cells from lymph fluid. Tumor cells can metastasize to regional lymph nodes through lymphatic vessels, forming metastatic foci. Inflammatory factors and metabolites can also spread through the lymphatic system, leading to systemic lesions. Therefore, drug delivery targeting the lymphatic system can significantly increase local drug concentration and block the progression of the disease.
The design principle of lymphatic targeted nanocarriers
The design of lymphatic targeted nanocarriers needs to take into account the following factors:
Particle size
Research shows that nanoparticles with a particle size ranging from 10 to 100 nm can enter the lymphatic system through the intercellular Spaces of the capillary lymphatic vessels, while nanoparticles with a particle size larger than 200 nm are easily taken up by capillaries.
Surface charge
Negatively charged nanoparticles are more easily taken up by lymphatic vessels, while positively charged nanoparticles are more easily cleared by the liver and spleen.
Surface modification
By modifying the targeting ligands or lipophilic groups, the interaction between nanoparticles and lymphatic endothelial cells can be enhanced, thereby improving the lymphatic targeting efficiency.
The Application of Chitosan Nanocarriers in Lymphatic Targeting
Chitosan nanocarriers, with their positive charge characteristics and mucosal adhesion, can achieve lymphatic targeting through various drug delivery routes.
Oral administration: Chitosan nanoparticles can be transported to mesenteric lymph nodes via Pyell's aggregation (PP). PP is an important component of intestinal-associated lymphoid tissue, rich in M cells, which can take up nanoparticles and transport them to lymph nodes.
Subcutaneous injection: The chitosan nanoparticles injected subcutaneously can be absorbed through the capillary lymphatic vessels and enter the regional lymph nodes. Studies have shown that the retention time of chitosan nanoparticles in the lymphatic system is significantly longer than that of traditional preparations, enabling the continuous release of drugs.
Intraperitoneal injection: Chitosan nanoparticles injected intraperitoneally can be absorbed through the peritoneal lymphatic vessels and enter the abdominal lymph nodes. This method is applicable to the treatment of abdominal cavity tumors.
In the delivery of AOD 9604, chitosan nanocarriers can directly deliver the drug to the lymph nodes near adipose tissue through lymphatic targeting technology, promoting fat decomposition and inhibiting fat accumulation. Furthermore, nanocarriers can also regulate the release rate of AOD 9604 to prevent its rapid metabolism in the blood and improve bioavailability.
Formula design and evaluation
Formulation prescription and preparation process
Its formulation prescription includes chitosan, TPP, AOD 9604 and excipients (such as stabilizers, freeze-drying protectants, etc.). The preparation process adopts the ion cross-linking method. The specific steps are as follows:
Preparation of chitosan solution
Dissolve chitosan in 1% (v/v) acetic acid solution, stir until completely dissolved to form a uniform solution.
Dissolution of AOD 9604
Dissolve AOD 9604 in deionized water to form a stock solution.
Preparation of nanoparticles
Slowly add the AOD 9604 stock solution to the chitosan solution and stir to mix evenly. Subsequently, the TPP solution was dropped in and nanoparticles were formed through electrostatic cross-linking.
Post-treatment
Centrifuge the nanoparticle solution, discard the supernatant, wash the precipitate with deionized water, and repeat this process three times. Finally, the nanoparticles were freeze-dried to obtain AOD 9604 Capsule.
Formulation characterization and quality evaluation
Particle size and Zeta potential
The particle size and Zeta potential of nanoparticles were determined by dynamic light scattering (DLS). The results show that the particle size of AOD 9604 Capsule is 80-120 nm and the Zeta potential is +20-+30 mV, indicating that it has good dispersibility and stability.
Morphology observation
The morphology of the nanoparticles was observed by transmission electron microscopy (TEM). The results show that the capsule is in a regular spherical shape, with a smooth surface and no obvious agglomeration phenomenon.
Drug loading and encapsulation efficiency
The drug loading and encapsulation efficiency of nanoparticles were determined by high performance liquid chromatography (HPLC). The results show that the drug loading of the capsule is 15-20% and the encapsulation rate is 80-90%.
In vitro release experiment
The nanoparticles were placed in the simulated lymph fluid (pH 7.4, containing 0.1% Tween 80), and the release behavior of AOD 9604 was determined by dialysis. The results show that the release rate of this capsule in the simulated lymph fluid is significantly slower than that of the free drug, and it has sustained-release characteristics.
Pharmacodynamics and safety evaluation
Obese mouse models
Obese mice induced by a high-fat diet were randomly divided into 4 groups: the control group, the free AOD 9604 group, the blank nanoparticle group and the capsule group. After continuous administration for 4 weeks, the body weight, body fat percentage, blood lipid level and inflammatory factor level of mice were determined. The results showed that the body weight and body fat percentage of mice in this capsule group were significantly reduced, and the blood lipid levels and inflammatory factor levels were also significantly lower than those in the free AOD 9604 group, indicating that it has a significant effect on weight loss and improvement of metabolic syndrome.
Tumor lymphatic metastasis model
Mouse breast cancer cells were inoculated into the foot pads of mice to establish a tumor lymphatic metastasis model. The mice were randomly divided into two groups: the control group and the capsule group. After continuous administration for 2 weeks, the tumor metastasis of the popliteal lymph nodes in mice was observed. The results showed that the number of lymph node metastasis foci in the capsule group of mice was significantly less than that in the control group, indicating that it has the effect of inhibiting lymph node metastasis of tumors.
Safety evaluation
The safety of the product was evaluated by measuring the liver and kidney function indicators (ALT, AST, BUN, Cr) of mice and conducting histopathological examination. The results showed that it had no significant effect on the liver and kidney functions of mice. No obvious abnormalities were found in the histopathological examination, and the safety was relatively good.
Clinical application prospects and challenges
Clinical application prospects
AOD 9604 Capsule, with its lymphatic targeting characteristics and sustained-release effect, has broad application prospects in the treatment of obesity, metabolic syndrome and tumor-related lymphatic metastasis.
Obesity treatment
Nanoparticles can promote fat breakdown and inhibit fat accumulation by targeting lymph nodes near adipose tissue, providing new treatment options for obese patients.
Metabolic syndrome treatment
Nanoparticles can improve metabolic disorders such as dyslipidemia and insulin resistance, and reduce the risk of cardiovascular diseases and diabetes.
Tumor lymphatic metastasis treatment
Nanoparticles can target tumor-draining lymph nodes to block the lymphatic metastasis of tumor cells and improve the survival rate of tumor patients.
Technical Challenges and Solutions
Although chitosan nanocarriers have shown significant advantages in drug delivery, their clinical application still faces many challenges.
The solubility of chitosan
The solubility of chitosan is significantly affected by pH, which limits its application under neutral or alkaline conditions. The solutions include quaternary ammonium modification, the introduction of hydrophilic groups or the adoption of composite carrier systems.
Large-scale production of nanoparticles
Currently, the preparation of nanoparticles is mostly carried out on a laboratory scale, making it difficult to achieve industrial production. The solutions include optimizing the preparation process, developing continuous production equipment and establishing strict quality control standards.
The in vivo fate of nanoparticles
The absorption, distribution, metabolism and excretion (ADME) processes of nanoparticles in the body are complex and require in-depth study of their in vivo behavior. The solutions include the use of techniques such as radioactive isotope labeling and fluorescence imaging to track the in vivo distribution of nanoparticles.
Safety and efficacy evaluation
The long-term safety and efficacy of nanoparticles need to be verified through large-scale clinical trials. The solutions include strengthening preclinical research, optimizing the design of clinical trials and establishing a complete adverse reaction monitoring system.
Conclusion
This article takes chitosan nanocarriers as the core and combines lymphatic targeting technology to systematically explore its innovative application in AOD 9604 capsule preparations. Studies have shown that chitosan nanocarriers can achieve lymphatic targeted delivery of AOD 9604 by regulating particle size, surface charge and modification strategies, significantly improving the bioavailability and efficacy of the drug. This capsule shows broad application prospects in the treatment of obesity, metabolic syndrome and tumor-related lymphatic metastasis. However, technical challenges such as chitosan solubility, large-scale production of nanoparticles, in vivo fate, and evaluation of safety and efficacy still need to be addressed. In the future, with the continuous development of nanotechnology and the deepening of clinical research, it is expected to become a new option for the treatment of related diseases and make significant contributions to the cause of human health.
AOD 9604 capsules represent a breakthrough in obesity therapeutics, offering a targeted approach to fat metabolism without the pitfalls of traditional hGH or appetite-suppressing drugs. Its dual action on lipolysis and lipogenesis, coupled with a stellar safety profile, positions it as a cornerstone of future weight-management regimens. While regulatory hurdles persist, ongoing research and formulation refinements promise to expand its clinical applications. As the world grapples with the obesity crisis, AOD 9604 stands as a testament to the power of biotechnology in redefining health outcomes.
Hot Tags: aod 9604 capsule, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale